UnitedHealth: The Cure For The AI Blues

UnitedHealth Group remains a Buy after a strong Q2, with robust earnings, raised guidance, and a doubled buyback authorization. UNH benefits from the market rotation out of AI and into defensive healthcare, positioning it as a sector leader. AI investments at UNH focus on margin expansion through operational efficiency, not speculative growth, leveraging its vast data assets. Valuation is less compelling than in April, but forward earnings, sector rotation, and buybacks still offer attractive upside.

Back in April, I called UnitedHealth Group Incorporated ( UNH ) the best house in a broken neighborhood and argued the CMS reimbursement decision was the catalyst that would start repricing